Product Information
LABETALOL HCL 200 MG TABLET is a generic product labeled by Biocon Pharma Inc., priced at $0.1395 per EA under NDC 70377006112. Its NADAC has been published 269 times since Aug 11, 2021.
FDA first approved this application on Jun 20, 2018. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the Labetalol Hydrochloride market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
200 mg/1
Manufacturer
Biocon Pharma Inc.NDC
70377006112
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
LABETALOL HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA209603FDA Approved
6/20/2018
TE Code
AB
On Market Since
5/27/2021
Pharmacological Classes
Price Statistics
The NADAC for LABETALOL HCL 200 MG TABLET has been published 269 times since Aug 11, 2021, and over the history we have for it it has declined 30.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1395 per EA |
|---|---|
| All-time high | $0.2060 (Sep 15, 2021) |
| All-time low | $0.1222 (Nov 20, 2024) |
| 52-week high | $0.1473 |
| 52-week low | $0.1395 |
| Median price | $0.1550 |
| Average price | $0.1588 |
| Largest weekly change | -25.6% (Apr 17, 2024) |
| Weeks tracked | 269 |
| Tracking since | Aug 11, 2021 |
Generic Alternatives
The matcher finds 12 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Biocon Pharma Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Labetalol Hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
beta-Adrenergic Blocker class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of LABETALOL HCL 200 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for LABETALOL HCL 200 MG TABLET, manufactured by Biocon Pharma Inc., is $0.1395 per EA (NDC 70377006112), effective Sep 30, 2026.
How has the price of LABETALOL HCL 200 MG TABLET changed over time?
Over the history we have for it, the NADAC for LABETALOL HCL 200 MG TABLET has declined 30.7%. It has been tracked across 269 weekly CMS publications since Aug 11, 2021.
What are the highest and lowest recorded NADAC prices for LABETALOL HCL 200 MG TABLET?
Since Aug 11, 2021, the NADAC for LABETALOL HCL 200 MG TABLET has ranged from a low of $0.1222 (Nov 20, 2024) to a high of $0.2060 (Sep 15, 2021), with a median of $0.1550 per EA.
Are there cheaper alternatives to LABETALOL HCL 200 MG TABLET?
12 manufacturers publish a NADAC-priced product with the same active ingredient and strength as LABETALOL HCL 200 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures LABETALOL HCL 200 MG TABLET?
LABETALOL HCL 200 MG TABLET (NDC 70377006112) is labeled by Biocon Pharma Inc., and CMS classifies it as a generic product.